9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Items 301–400 of 975
Kalas, M. A., Dang, T. Q., Galura, G. M., Alvarado, L. A., Dwivedi, A. K., Deoker, A., & McCallum, R. W. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2022-002480 · Cited by 16
Wang, D., Liu, J. Y., Zhong, L., Ding, L., Zhang, Q., Yu, M., Li, M., & Xiao, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1004617 · Cited by 18
Li, Y., Hu, H. Z., Zheng, Y., Donahoo, W. T., Guo, Y. M., Xu, J., Chen, W., Liu, N., Shenkman, E. A., Bian, J., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054036 · Cited by 18
Progression from prediabetes to type 2 diabetes mellitus in adolescents: a real world experience
Weiner, A., Zhang, M., Ren, S., Tchang, B. G., Gandica, R., & Murillo, J. E. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1181729 · Cited by 20
Neeland, I. J., Arafah, A., Bourges-Sevenier, B., Dazard, J.-E., Albar, Z., Landskroner, Z., Tashtish, N., Eaton, E., Friswold, J., Porges, J., et al. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100630 · Cited by 19
“%) and, as defined by the 2021 ADA Professional Practice Committee pathway [4], those with established or at high-risk for atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and/or chronic heart failure with reduced ejection fraction (HFrEF).”
BackgroundGlycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
Bonifácio, M., Benfato, I. D., Cruz, M. D. A., de Sales, D. C., Pandolfo, I. L., Quintana, H. T., Carvalho, C. P. D. F., de Oliveira, C. A. M., & Rennó, A. C. M. (2021) · Lasers in Medical Science · doi:10.1007/s10103-021-03434-7 · Cited by 19
Lee, Y., Hsu, C., Fu, C.-M., Wang, S., Huang, C.-C., & Li, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.781379 · Cited by 22
Richardson, B., Khan, M. Q., Brown, S. A., Watt, K. D. S., & Izzy, M. J. (2021) · Hepatology Communications · doi:10.1002/hep4.1876 · Cited by 19
Loh, D. K. W., Kadirvelu, A., & Pamidi, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144193 · Cited by 19
Tudoran, C., Tudoran, M., Giurgi-Oncu, C., Abu-Awwad, A., Abu-Awwad, S.-A., & Voiţă-Mekereş, F. (2023) · Medicina · doi:10.3390/medicina59101760 · Cited by 19
“The comprehensive reviews of Scheen and Savarese et al. [16,41], published in 2022, summarize extensive information on the interaction between the most important classes of GLA and VA, specifically SCA, as well as the current guidelines recommendations for the administration of each class [1,43,44].”
BackgroundInfluentialNoh, Y., Yin, H., Yu, O. H. Y., Bitton, A., & Azoulay, L. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03420 · Cited by 18
Tanaka, Y., Iwaya, C., Kawanami, T., Hamaguchi, Y., Horikawa, T., Shigeoka, T., Yanase, T., Kawanami, D., & Nomiyama, T. (2021) · Diabetology International · doi:10.1007/s13340-021-00560-z · Cited by 18
Murao, S., Murao, K., Nagata, T., Shimizu, M., & Miyai, Y. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13753 · Cited by 16
Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure
Jang, S. Y., & Yang, D. H. (2022) · International Journal of Heart Failure · doi:10.36628/ijhf.2021.0039 · Cited by 18
Zhang, Z., Leng, Y., Fu, X., Yang, C., Xie, H., Yuan, H., Liang, Q., Gao, H., & Xie, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918681 · Cited by 15
“The current treatment for T2DM is based on a combination of blood glucose regulation, blood pressure control, lipid lowering, microcirculation improvement and lifestyle intervention (ADA, 2021).”
Abegaz, T. M., Ahmed, M. B., Sherbeny, F., Diaby, V., Chi, H., & Ali, A. A. (2023) · Healthcare · doi:10.3390/healthcare11081138 · Cited by 22
The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy
Lemos, G., Fernandes, C. M. A. D. S., Silva, F. H., & Calmasini, F. B. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00793-4 · Cited by 17
“Metformin is an oral antihyperglycemic drug of the biguanide class, considered a fi rst-choice pharmacological agent for the treatment of type 2 diabetes [96].”
Alexander, J. T., Staab, E. M., Wan, W., Franco, M. I., KNITTER, A. C., Skandari, M. R., Bolen, S. D., Maruthur, N. M., Huang, E. S., Philipson, L. H., et al. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07227-0 · Cited by 21
Lau, K. T. K., Wong, C. K. H., Au, I. C. H., Lau, W. C. Y., Man, K. K. C., Chui, C. S. L., & Wong, I. C. K. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023489 · Cited by 16
Kawaguchi, Y., Miyamoto, S., Hajika, Y., Ashida, N., Hirota, T., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02138-w · Cited by 15
Ruissen, M. M., Montori, V. M., Hargraves, I. G., Branda, M. E., León‐García, M., de Koning, E. J. P., & Kunneman, M. (2023) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2022-112067 · Cited by 17
Alkabbani, W., Zongo, A., Minhas‐Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002496 · Cited by 19
Recent developments in adjunct therapies for type 1 diabetes
Timmons, J. G., Littlejohn, L., Boyle, J. G., & Petrie, J. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159806 · Cited by 17
Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes
Orchard, S. G., Lockery, J. E., Broder, J. C., Ernst, M. E., Espinoza, S. E., Gibbs, P., Wolfe, R. S., Polekhina, G., Zoungas, S., Loomans-Kropp, H. A., et al. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad017 · Cited by 18
Metformin Use and Long-term Clinical Outcomes in Kidney Transplant Recipients
Kwon, S., Kim, Y. C., Kwon, H., Cho, J., Kim, C., Son, H. E., Jeong, J.-C., Jung, I. M., Yoo, K. D., Kim, Y.-J., et al. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.01.446 · Cited by 16
Drug-related problems in elderly patients with diabetes: A study in primary health care setting
Cahyaningsih, I., Hikmah, N., & Maziyyah, N. (2023) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/rgpup8aeb3 · Cited by 14
Combination of Pioglitazone and Metformin Actions on Liver Lipid Metabolism in Obese Mice
Liu, J. Y., Wang, D., Xie, Z., Ding, L., Li, S., Ma, X.-M., Liu, J., Ren, J., Xiao, C., Yang, C., et al. (2023) · Biomolecules · doi:10.3390/biom13081199 · Cited by 15
Tan, Y., Liu, S., Huang, M., Cheng, H., Xu, B., Luo, H., & Tang, Q. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1316269 · Cited by 14
“Globally, 9% of health expenditure is spent on diabetes, amounting to $966 billion (1, 9).”
BackgroundAlshaya, O. A., Korayem, G. B., Alghwainm, M., Alyami, W., Alotaibi, A., Yami, M. S. A., & Almohammed, O. A. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102054 · Cited by 17
“The overall high prevalence of metformin use aligns with adherence to previous guidelines that underscored the initiation of metformin as the first-line therapy for T2DM (Davies et al., 2018, American Diabetes Association, 2021).”
Pradhan, R., Yin, H., Lu, S., Sebastiani, G., Yu, O. H. Y., Suissa, S., & Azoulay, L. (2025) · Diabetes Care · doi:10.2337/dc24-1903 · Cited by 16
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
Seetharaman, R., Pawar, S. R., & Advani, M. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15100 · Cited by 17
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1985465 · Cited by 19
Unger, J., Allison, D. C., Kaltoft, M. S., Lakkole, K., Panda, J. K., Ramesh, C. K., Sargın, M., Smolyarchuk, Е. А., Twine, M., Wolthers, B. O., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14566 · Cited by 19
Muniz, T. P., Araújo, D. V., Savage, K. J. J., Cheng, T., Saha, M., Song, X., Gill, S., Monzon, J. G., Grenier, D., Genta, S., et al. (2021) · Cancers · doi:10.3390/cancers14010089 · Cited by 16
Diabetes mellitus and multiple myeloma; common features of two distinct entities
Tentolouris, A., Ntanasis‐Stathopoulos, I., Eleftheriadou, I., Malandrakis, P., Tzeravini, E., & Gavriatopoulou, M. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3535 · Cited by 16
Hanna, J. M., Nargesi, A. A., Essien, U. R., Sangha, V., Lin, Z., Krumholz, H. M., & Khera, R. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100370 · Cited by 15
SGLT2 Inhibitors and Peripheral Vascular Events
Marchiori, E., Rodionov, R. N., Peters, F., Magnussen, C., Nordanstig, J., Gombert, A., Spanos, K. T., Jarzebska, N., & Behrendt, C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.001 · Cited by 16
Cucinotta, D., Nicolucci, A., Giandalia, A., Lucisano, G., Manicardi, V., Mannino, D., Rossi, M. C., Russo, G. T., & Bartolo, P. D. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109096 · Cited by 15
Shao, H., Li, P., Guo, J., Fonseca, V., Shi, L., & Zhang, P. (2022) · Diabetes Care · doi:10.2337/dc21-1800 · Cited by 13
Khawaji, A., A. Jaly, A., A. Bakri, H., Ravi, R., Hattan, A., Khawaji, A., & Najmi, W. (2025) · Journal of Obesity · doi:10.1155/jobe/3442754 · Cited by 13
“Nonetheless, it is currently unknown whether tirzepatide can produce cardiovascular advantages comparable to those of specifc GLP-1 RAs or sodium–glucose Cotrans-porter 2 inhibitors [43].”
Xu, J., Zhang, Y., Li, Y., Zhao, X., Zhou, W., Loghin, C., Tham, L. S., Cui, X., Cui, Y., & Wang, W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01921-5 · Cited by 13
Engström, M. S., Johansson, U., Leksell, J. K., Linder, E., & Eeg‐Olofsson, K. (2022) · JMIR Diabetes · doi:10.2196/34561 · Cited by 14
Meta-Analysed Numbers Needed to Treat of Novel Antidiabetic Drugs for Cardiovascular Outcomes
Wolff, G., Lin, Y., Akbulut, C., Brockmeyer, M., Parco, C., Hoss, A., Sokolowski, A., Westenfeld, R., Kelm, M., Roden, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14213 · Cited by 13
Lü, Y., & Guo, C. (2023) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986231178126 · Cited by 21
Wang, M., Cai, X., LIANG, R., Zhang, E.-M., Liang, X.-Q., Liang, H., Fu, C. L., Zhou, A.-D., Shi, Y. Y., Xu, F. L., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115515 · Cited by 14
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
Andraos, J., Smith, S. R., Tran, A., & Pham, D. Q. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01406-6 · Cited by 20
Feng, W., Wu, H., Ma, H., Yin, Y., Tao, Z., Lü, S., Zhang, X., Yu, Y., Wan, C., & Liu, Y. (2025) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2025.105801 · Cited by 16
The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Tilinca, M. C., Tiucă, R. A., Ţilea, I., & Varga, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121249 · Cited by 15
Wood, M. E., Patorno, E., Huybrechts, K. F., Bateman, B. T., Gray, K. J., Seely, E. W., Vine, S. M., & Hernández–Díaz, S. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.319 · Cited by 13
Kobayashi, K., Toyoda, M., Hatori, N., Sakai, H., Furuki, T., Chin, K., Kimura, M., Saito, N., Kanaoka, T., Aoyama, T., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109231 · Cited by 16
Alkabbani, W., Zongo, A., Minhas‐Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. (2022) · Diabetic Medicine · doi:10.1111/dme.14858 · Cited by 12
Szépkúti, S., Bandur, S., Kovács, G., Ferenci, T., Svébis, M. M., Turbucz, P., & Tabák, Á. G. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01139-8 · Cited by 15
“Long-acting basal insulins improve glycaemic control through decreasing fasting plasma glucose (FPG) and are used alone or in combination with OADs in type 2 diabetes uncontrolled with non-insulin therapies [4, 5].”
BackgroundBrockmeyer, M., Wies, E., Joerges, J., Sommer, J., Borgmann, S. O., Chernyak, N., Lin, Y., Parco, C., Schulze, V., Heinen, Y., et al. (2022) · Clinical Cardiology · doi:10.1002/clc.23948 · Cited by 19
Li, F., Wang, Y., Yu, H., Gao, X., Li, L., Sun, H., & Qin, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1075421 · Cited by 17
Scutca, A.-C., Nicoară, D.-M., Mărăzan, M., Brad, G.-F., & Mărginean, O. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010221 · Cited by 15
Continuity of Medication Use by US Adults With Diabetes, 2005-2019
Chehal, P. K., Uppal, T. S., Turbow, S. D., Fernandes, G. F., HAW, J. S., Shah, M. K., Rajpathak, S. N., Narayan, K. M. V., & Ali, M. K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.53562 · Cited by 13
Freeman, M. W., Bond, M., Murphy, B., Hui, J., & Isaacsohn, J. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00572-x · Cited by 13
IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases
Zhao, J., Turpin-Nolan, S. M., & Febbraio, M. A. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155549 · Cited by 12
Autophagy: Shedding Light on the Mechanisms and Multifaceted Roles in Cancers
You, H., Wang, L., Meng, H., Li, J., & Fang, G.-Y. (2025) · Biomolecules · doi:10.3390/biom15070915 · Cited by 16
AlRuthia, Y. S., Bahari, O. H., Alghnam, S. A., Alrumaih, A. M., Asiri, H. M., Alshammari, M., Alhowimel, M., & Alabdulkarim, H. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.852721 · Cited by 12
Hu, S., Gu, S., Qi, C., Wang, S., Qian, F., Shi, C., & Fan, G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14881 · Cited by 12
“Consequently, GLP-1 RAs are used as primary therapies for patients with type 2 diabetes with atherosclerotic CV disease and relatively highrisk factors according to the American Diabetes Association (ADA) guidelines.(9)”
BackgroundCalzada, F., Valdes, M., Martínez-Solís, J., Velázquez, C., & Barbosa, E. (2023) · Pharmaceuticals · doi:10.3390/ph16050724 · Cited by 11
Factors Associated with Increased Intraocular Pressure in Type 2 Diabetes Patients
Braha, A., Simion, A., Timar, R. Z., & Timar, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030676 · Cited by 16
O’Hara, D. V., Janse, R. J., Fu, E. L., Jardine, M., & Carrero, J. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111745 · Cited by 15
Gomaa, M. S., Alturki, M. S., Tawfeeq, N., Hussein, D. A., Pottoo, F. H., Khzem, A. H. A., Sarafroz, M., & Abubshait, S. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121607 · Cited by 14
Russo, G. T., Monami, M., Perseghin, G., Avogaro, A., Filardi, P. P., Senni, M., Borghi, C., & Maggioni, A. P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01045-7 · Cited by 12
Qu, X., Qi, G., Sun, D., Yue, J., Xu, W., & Xu, S. (2021) · Talanta · doi:10.1016/j.talanta.2021.122442 · Cited by 12
Koike, M., Saito, H., Kohno, G., Takubo, M., Watanabe, K., & Ishihara, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111463 · Cited by 12
Doan, T., Park, E. J., Cho, H. M., Ryu, B., Lee, B.-W., Thuong, P.-T., & Oh, W. K. (2021) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00785 · Cited by 13
Liao, P.-Y., Lo, H., Liu, I.-C., Lo, L.-C., Hsiang, C., & Ho, T. (2021) · Food & Function · doi:10.1039/d1fo03620c · Cited by 12
Nawata, K. (2021) · Health · doi:10.4236/health.2021.1312102 · Cited by 12
Márkus, B., Hargittay, C., Iller, B., Rinfel, J., Bencsik, P., Oláh, I., Kalabay, L., & Vörös, K. (2022) · BMC Family Practice · doi:10.1186/s12875-021-01615-5 · Cited by 18
Sönmez, A., Sabbour, H. M., Echtay, A. S., Rahmah, A. M., Alhozali, A. M., Sabaan, F. S. A., Haddad, F., Iraqi, H., Elebrashy, I., Assaad, S. N., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13266 · Cited by 16
Gorst‐Rasmussen, A., & Tarp-Johansen, M. J. (2022) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2022.2058525 · Cited by 15
Letta, S., Aga, F., Yadeta, T. A., Geda, B., & Dessie, Y. (2022) · SAGE Open Medicine · doi:10.1177/20503121221107337 · Cited by 21
Zhang, Y., Chen, Z., & Tian, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.991087 · Cited by 16
Frías, J. P., Bonora, E., Ruiz, L. N., Hsia, S. H., Jung, H., Raha, S., Cox, D. A., Bethel, M. A., & Кониг, М. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14469 · Cited by 11
Kalluri, S. R., Bhutta, T. H., Hannoodee, H., Khalili, M. A., Theik, N. W. Y., Raji, O. E., Shenwai, P., Shah, R., & Khan, S. (2021) · Cureus · doi:10.7759/cureus.17668 · Cited by 17
Oe, Y., Nomoto, H., Nakamura, A., Kuwabara, S., Takahashi, Y., Yasui, A., Izumihara, R., Miya, A., Kameda, H., Cho, K. Y., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/5603864 · Cited by 12
Scheen, A. J. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100054 · Cited by 12
Cantor, J. C., Chakravarty, S., Farnham, J., Nova, J., Ahmad, S., & Flory, J. (2022) · Medical Care · doi:10.1097/mlr.0000000000001696 · Cited by 11
Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Papaetis, G. S. (2022) · Current Drug Safety · doi:10.2174/1574886317666220304124756 · Cited by 13
IDRIS, I. R., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14799 · Cited by 12
Type 2 diabetes and cardiovascular disease: risk reduction and early intervention
Hinnen, D., Kruger, D. F., & MAGWIRE, M. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2126235 · Cited by 21
Jiang, Y., Jiang, F., Li, M., Wu, Q., Xu, C., Zhang, R., Song, M., Wang, Y., Wang, Y., Chen, Y., et al. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04374-8 · Cited by 10
Glynn, A., Hernandez, I., & Roberts, E. T. (2022) · Health Services Research · doi:10.1111/1475-6773.13990 · Cited by 12
Xiong, S., Liu, W., Song, Y., Du, J., Wang, T., Zhang, Y., Huang, Z., He, Q., Dong, C., Yu, Z., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.813917 · Cited by 14
Powell, M. A., Clark, C. N., Alyakin, A., Vogelstein, J. T., & Hart, B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.41505 · Cited by 14
Bianzano, S., Nordaby, M., Plum‐Mörschel, L., Peil, B., & Heise, T. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14932 · Cited by 12
Singh, H., Sharma, J., Sikarwar, P., & Kakkar, A. K. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2161045 · Cited by 11
Verma, S., Sabbour, H. M., Alamuddin, N., Alawadi, F., Alkandari, H., Almahmeed, W. A., Assaad-Khalil, S. H., HADDAD, J. A., Lombard, L., Malik, R. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15011 · Cited by 11
Huynh, D. J., Renelus, B. D., & Jamorabo, D. S. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0814 · Cited by 19
“Metformin is the standard first-line oral treatment for T2DM, but some patients require additional therapy, such as glucagon-like peptide-1 receptor agonists (GLP1-RAs), to achieve healthy blood sugar levels [6,7].”
Li, J., Zhu, C., Liang, J., Hu, J., Liu, H., Wang, Z., Guan, R., Chow, J., Yan, S., Li, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303694 · Cited by 13
State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization
Anderson, K. E., Chaiyakunapruk, N., Gutierrez, E. J., Schmutz, H. W., Rose, M. R., Brixner, D. I., & McQueen, R. B. (2024) · Health Affairs · doi:10.1377/hlthaff.2024.00118 · Cited by 15
Unnikrishnan, R., Radha, V., & Mohan, V. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s271582 · Cited by 13
Starr, J. A., Pinner, N. A., Lisenby, K. M., & Osmonson, A. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2527 · Cited by 15
National Asthma Education and Prevention Program 2020 Guidelines: What’s Important for Primary Care
Murphy, M. (2021) · The Journal of Family Practice · doi:10.12788/jfp.0219 · Cited by 16
Tanaka, A., Toyoda, S., Imai, T., Shiina, K., Tomiyama, H., Matsuzawa, Y., Okumura, T., Kanzaki, Y., Onishi, K., Kiyosue, A., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01369-5 · Cited by 13
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.